(19)
(11) EP 0 708 829 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.07.2004 Bulletin 2004/30

(45) Mention of the grant of the patent:
28.01.2004 Bulletin 2004/05

(21) Application number: 94922265.7

(22) Date of filing: 06.07.1994
(51) International Patent Classification (IPC)7C12N 15/11, C07H 21/04, A61K 31/70
(86) International application number:
PCT/EP1994/002218
(87) International publication number:
WO 1995/002051 (19.01.1995 Gazette 1995/04)

(54)

A PHARMACEUTICAL COMPOSITION COMPRISING ANTISENSE-NUCLEIC ACID FOR PREVENTION AND/OR TREATMENT OF NEURONAL INJURY, DEGENERATION AND CELL DEATH AND FOR THE TREATMENT OF NEOPLASMS

ANTISENSE-NUKLEINSÄURE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VORBEUGUNG UND/ODER BEHANDLUNG VON NEURONALEN VERLETZUNGEN, ENTARTUNGEN UND ZELLTOD, UND ZUR BEHANDLUNG VON NEOPLASMEN

COMPOSITION PHARMACEUTIQUE COMPRENANT DE L'ACIDE NUCLEIQUE ANTISENS UTILISE DANS LA PREVENTION ET/OU LE TRAITEMENT DE LESIONS NEURONALES, DE LA DEGENERESCENCE ET DE LA MORT CELLULAIRE AINSI QUE DANS LE TRAITEMENT DES NEOPLASMES


(84) Designated Contracting States:
AT BE CH DE FR GB IT LI

(30) Priority: 10.07.1993 EP 93111059

(43) Date of publication of application:
01.05.1996 Bulletin 1996/18

(73) Proprietor: BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH
D-37079 Göttingen (DE)

(72) Inventors:
  • SCHLINGENSIEPEN, Georg-F.
    D-37073 Göttingen (DE)
  • SCHLINGENSIEPEN, Reimar
    D-37073 Göttingen (DE)
  • SCHLINGENSIEPEN, Karl-Hermann
    D-37120 Göttingen (DE)
  • BRYSCH, Wolfgang
    D-37073 Göttingen (DE)

(74) Representative: Meyers, Hans-Wilhelm, Dr.Dipl.-Chem. et al
Patentanwälte von Kreisler-Selting-Werner Postfach 10 22 41
50462 Köln
50462 Köln (DE)


(56) References cited: : 
EP-A- 0 305 929
WO-A-92/15680
   
  • WICKSTROM, E. 'Prospects for antisense nucleic acid therapy of cancer and AIDS'; 1991, WILEY-LISS, Inc., NEW YORK, USA; pages 83-114, MERCOLA, D. cited in the application
  • ERICKSON, R. & IZANT, J. 'Gene regulation: biology of antisense RNA and DNA'; 1992 RAVEN PRESS, Ltd., NEW YORK, USA; pages 285-293, BRADLEY, M. et al.
  • NATURE, vol.332, 10 March 1988, LONDON GB pages 166 - 171 ANGEL, P. ET AL. 'Oncogene jun encodes a sequence-specific trans-activator similar to AP-1'
  • JOURNAL OF BIOLOGICAL CHEMISTRY, vol.267, no.27, 25 September 1992, BALTIMORE, MD US pages 19665 - 19672 NICOLAIDES, N. ET AL. 'The Jun family members, c-jun and junD, transactivate the human c-myb promoter via an Ap1-like element'
  • PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol.32, March 1991 page 303 SCHLINGENSIEPEN, K.-H. & BRYSCH, W. 'Proto-oncogenes c-jun and jun-B have opposite effects on cell proliferation' cited in the application & 82nd Annual Meeting of the American Association for Cancer Research; May 15-18, 1991; HOUSTON, USA
  • JOURNAL OF CELLULAR BIOCHEMISTRY, vol.17A, 1993 page 208 SCHLINGENSIEPEN, K.-H. ET AL. 'Function of junB and c-jun in the differentiation of neurons and PC-12 tumor cells' cited in the application & Keystone Symposia on Molecular & Cellular Biology; January 9-31, 1993
  • BIOMEDICINE & PHARMACOTHERAPY, vol.46, no.5-7, 1992 page 257 SCHLINGENSIEPEN, K.-H. & BRYSCH, W. 'Specific inhibition of different jun genes either inhibits or stimulates cell differentiation' cited in the application & 5th International Congress on Differentiation Therapy; September 2-5, 1992; VILLASIMIUS, Italy
  • DEVELOPMENTAL GENETICS, vol.14, 20 September 1993 pages 305 - 312 SCHLINGENSIEPEN, K.-H. ET AL. 'Opposite functions of jun-B and c-jun in growth regulation and neuronal differentiation' cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).